Pertuzumab: Difference between revisions
Carlo Banez (talk | contribs) - noting FDA approval |
Carlo Banez (talk | contribs) - link to FDA information |
||
| Line 13: | Line 13: | ||
| ChemSpiderID = NA |
| ChemSpiderID = NA |
||
| tradename = Perjeta |
| tradename = Perjeta |
||
| licence_US = Pertuzumab |
|||
| pregnancy_AU = |
| pregnancy_AU = |
||
| pregnancy_US = |
| pregnancy_US = D |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = |
||
Revision as of 13:00, 11 June 2012
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | HER2 |
| Clinical data | |
| Trade names | Perjeta |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.[2] Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012.[3] Roche acquired Genentech in 2009 and now owns the IP on Pertuzumab.
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.[4]
The dosage of pertuzumab used in the pivotal phase III CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial was as follows: IV 840 mg loading dose followed by IV 420 mg every three weeks.[5]
The pharmacokinetics of intravenous pertuzumab appear to be unaffected by age and no drug-drug interaction has been reported with docetaxel. The pharmacokinetics and pharmacodynamics of pertuzumab have recently been summarized in a review by Gillian Keating.[5]
The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects in the randomized, double-blind, multinational, phase III CLEOPATRA trial.[6]
Intravenous pertuzumab is currently being evaluated in patients with breast cancer in the following trials: MARIANNE (advanced breast cancer), NEOSPHERE (early breast cancer), TRYPHAENA (HER2-positive stage II/III breats cancer) and APHINITY (HER2-positive nonmetastatic breast cancer).[5]
References
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ de Bono, Johann S.; Bellmunt, J; Attard, G; Droz, JP; Miller, K; Flechon, A; Sternberg, C; Parker, C; Zugmaier, G (20 January 2007). "Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer". Journal of Clinical Oncology. 25 (3): 257–262. doi:10.1200/JCO.2006.07.0888. PMID 17235043.
- ^ "FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer" (Press release). Genentech. Retrieved 2012-06-09.
- ^ Genentech press release - May 15, 2005
- ^ a b c Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012 Feb 12; 72 (3): 353-60.Link text
- ^ Baselga J, Cortés J, Kim SB, and the CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012 Jan 12; 366 (2): 109-19. Link text
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
10.1056/NEJMoa1113216